Updated cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma
From the perspective of the Chinese health service system, the treatment of advanced GC/GEJC with tislelizumab combined with chemotherapy has a cost-effective advantage over chemotherapy alone.
Authors
- Weihong Ge
- Lei Xu (ORCID: https://orcid.org/0000-0002-8499-0448)
- Yunchun Long (ORCID: https://orcid.org/0000-0001-9918-5743)
- Yao Lü (ORCID: https://orcid.org/0000-0002-3380-7762)
- Hao Wang (ORCID: https://orcid.org/0000-0001-5461-0689)
Institutions
- Nanjing University of Chinese Medicine (CN)
- Xuzhou Medical College (CN)
- Meizhou City People's Hospital (CN)
- Nanjing Drum Tower Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-12-16
- DOI
- https://doi.org/10.3389/fonc.2024.1477722
- Citations
- 7
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.93